Therapeutic targets

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK government

DDW Highlights: 3 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere,… Read More

#Podcasts

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK #UK government

This week in Drug Discovery (26 – 30 January) 

News round-up for 26 – 30 January by Bruno Quinney, Content Team at DDW.  This week in DDW, discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere, why is the UK leading Europe’s biotech market? The top stories:    Parkinson’s could be identified in… Read More

#News

#Allergy #Immune cells #Therapeutic targets

Allergies could be treated by therapeutic target, study finds 

Researchers have uncovered a new target which could help treat severe allergic diseases.  In a study published in The Journal of Allergy and Clinical Immunology, a team led by Associate Professor Tomoaki Ando and Professor Jiro Kitaura at Juntendo University Graduate School of Medicine identified Fab (fragment antigen-binding) antibody… Read More

#News

Long Covid
#Covid-19 #Japan #Therapeutic targets

Long Covid breakthrough offers hope of new therapeutic target

Researchers from Yokohama City University in Japan have made a breakthrough in understanding Covid ‘brain fog’, providing clues for a new therapeutic target.  Researchers used a novel imaging technique to visualise AMPA receptors (AMPARs), key molecules for memory and learning, in the living brain. They… Read More

#News

Ion channel modulators
#CNS #Drug discovery #Ion channel modulators #Therapeutic targets #Webinar

Last chance: Discover opportunities in ion channel drug discovery

Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, will provide data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the… Read More

Webinar date:
Supported by Axxam
#News

Ion channel modulators
#CNS #Drug discovery #Ion channel modulators #Therapeutic targets #Webinar

Discover why ion channels don’t have to be difficult drug discovery targets

Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, will provide data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the… Read More

Webinar date:
Supported by Axxam
#News

Ion channel modulators
#CNS #Drug discovery #Ion channel modulators #Therapeutic targets #Webinar

Register now: Understand current and future ion channel targets

Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, will provide data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the… Read More

Webinar date:
Supported by Axxam
#News

Ion channel modulators
#CNS #Drug discovery #Ion channel modulators #Therapeutic targets #Webinar

Webinar: Current trends in ion channel drug discovery

Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, will provide data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the… Read More

Webinar date:
Supported by Axxam
#News

Ion channel modulators
#CNS #Drug discovery #Ion channel modulators #Therapeutic targets

Ion channel drug discovery – current trends and future opportunities

Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, provides data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the last… Read More

Webinar date:
Supported by Axxam
#Webinars

Cardiovascular system
#Cardiovascular disease #Therapeutic targets #University of Bristol

New treatment target for atheroschlerosis discovered

Scientists at the University of Bristol have uncovered a new disease driving mechanism which they are aiming to target to help treat the development of atherosclerotic plaques. The project to develop the new therapeutic, known as IMSET, is being led by Professor Jason Johnson, Professor of… Read More

#News

Knee x-ray
#Bone disease #Osteoporosis #Therapeutic targets #Tokyo University of Science

New study reveals promising drug target for treating osteoporosis

Researchers have identified a novel target downstream of parathyroid hormone (PTH) signalling that suppresses bone formation in osteoporosis. The PTH-derived peptide teriparatide has demonstrated strong bone promoting effects. However, it is also to known to exert bone-resorbing effects. A new study uncovers a novel… Read More

#News

#AI / data analytics / healthtech / informatics #Anti-inflammatory #Artificial intelligence (AI) #Cancer research #Covid-19 #EpicentRx #Immunology / Virology & Vaccines #Oncology #Polypharmacologic #Precision medicine #Protein binders #Therapeutic targets

New podcast on the significance of drug repurposing

This is the latest episode of the free DDW narrated podcast, titled “Why drug repurposing is so significant for drug discovery” which covers three written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: AI use in repurposing drugs for Covid-19 and RRx-001: Jack… Read More

#News

#Avacta #Cancer research #CAR-T #Cell therapy #Immunotherapy #Oncology #Precision medicine #T cell activation #Therapeutic targets

Precision cancer therapies: Where are we?

DDW’s Diana Spencer reports on the recent Avacta Therapeutics Science Day, which explored the latest exciting developments in precision and targeted treatments for cancer and asked what advances the future might bring. The Avacta Therapeutics Science Day brought together senior company scientists and international oncology experts to provide an overview… Read More

#Cancer Research #Exclusive Content

#Anti-inflammatory #Cancer research #EpicentRx #Oncology #Polypharmacologic #Precision medicine #Protein binders #Therapeutic targets

RRx-001: Jack of all trades, master of…many

Listen to this article on the DDW podcast: Bryan Oronsky, Chief Development Officer at EpicentRx, discusses how one drug sourced from the defense and aerospace industry, could have many potential disese targets. Introduction The term “dilettante”, at least in English, connotes a sloppy bungler, a smatterer, a second rater, unskilled and… Read More

#Exclusive Content

Man using microscope in lab
#Collaboration #Phenotyping #PhoreMost #Protein binders #Therapeutic targets

PhoreMost enters multi-target collaboration with Arvinas

PhoreMost and targeted protein degradation (TPD) specialists Arvinas have agreed a multi-target collaboration. Under the terms of the agreement, PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets. The output from SITESEEKER screening campaigns will be used to drive degrader drug discovery in oncology and neurodegeneration… Read More

#Business & Investment #News